Trials / Completed
CompletedNCT02044120
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan in Patients With Previously Treated,Incurable Ewing Sarcoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Sarcoma Alliance for Research through Collaboration · Academic / Other
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | niraparib | |
| DRUG | Temozolomide | |
| DRUG | Irinotecan |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
- First posted
- 2014-01-23
- Last updated
- 2021-01-12
Locations
5 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT02044120. Inclusion in this directory is not an endorsement.